share_log

Avalo Therapeutics | S-3/A: Registration statement for specified transactions by certain issuers (Amendment)

Avalo Therapeutics | S-3/A: Registration statement for specified transactions by certain issuers (Amendment)

Avalo Therapeutics | S-3/A:特定交易注册声明(修正)
美股sec公告 ·  07/29 16:10
Moomoo AI 已提取核心信息
Avalo Therapeutics, Inc. has filed an amendment to its FORM S-3 registration statement with the Securities and Exchange Commission (SEC) on July 29, 2024. The registration statement pertains to the potential sale of various securities by selling stockholders, including up to 22,357,897 shares of common stock issuable upon conversion of Series C Non-Voting Convertible Preferred Stock, 22,357.897 shares of Series C Non-Voting Convertible Preferred Stock, up to 11,967,526 shares of common stock issuable upon the exercise of warrants, and 11,967,526 warrants to purchase shares of common stock or Series C Non-Voting Convertible Preferred Stock. The registration statement includes details on the rights and preferences of the securities, indemnification agreements, and anti-takeover provisions. Avalo Therapeutics will not receive any proceeds from the sale...Show More
Avalo Therapeutics, Inc. has filed an amendment to its FORM S-3 registration statement with the Securities and Exchange Commission (SEC) on July 29, 2024. The registration statement pertains to the potential sale of various securities by selling stockholders, including up to 22,357,897 shares of common stock issuable upon conversion of Series C Non-Voting Convertible Preferred Stock, 22,357.897 shares of Series C Non-Voting Convertible Preferred Stock, up to 11,967,526 shares of common stock issuable upon the exercise of warrants, and 11,967,526 warrants to purchase shares of common stock or Series C Non-Voting Convertible Preferred Stock. The registration statement includes details on the rights and preferences of the securities, indemnification agreements, and anti-takeover provisions. Avalo Therapeutics will not receive any proceeds from the sale of securities by the selling stockholders but may receive proceeds from the exercise of warrants, which will be used for general corporate purposes. The company's common stock is listed on The Nasdaq Capital Market under the symbol 'AVTX', while the Series C Non-Voting Convertible Preferred Stock and warrants are not listed on any exchange.
Avalo Therapeutics, Inc.于2024年7月29日向证券交易委员会(SEC)提交了其S-3注册声明的修正案。注册声明涉及由售出股东潜在销售各种证券的事宜,包括最多22,357,897股普通股,可按照C系列无表决权可转换优先股的转换而发行;22,357.897股C系列无表决权可转换优先股;最多11,967,526股普通股,可按行权权证而发行;和11,967,526份购买普通股或C系列无表决权可转换优先股的认股权证。注册声明包括有关证券的权利和优先权、赔偿协议和防御措施的详细信息。Avalo Therapeutics不会从售出股东的证券销售中获得任何收益,但可能从行使权证中获得收益,用于一般公司用途。公司的普通股在纳斯达克资本市场上挂牌交易,代码为'AVTX',而C系列无表决权可转换优先股和权证未在任何交易所上市。
Avalo Therapeutics, Inc.于2024年7月29日向证券交易委员会(SEC)提交了其S-3注册声明的修正案。注册声明涉及由售出股东潜在销售各种证券的事宜,包括最多22,357,897股普通股,可按照C系列无表决权可转换优先股的转换而发行;22,357.897股C系列无表决权可转换优先股;最多11,967,526股普通股,可按行权权证而发行;和11,967,526份购买普通股或C系列无表决权可转换优先股的认股权证。注册声明包括有关证券的权利和优先权、赔偿协议和防御措施的详细信息。Avalo Therapeutics不会从售出股东的证券销售中获得任何收益,但可能从行使权证中获得收益,用于一般公司用途。公司的普通股在纳斯达克资本市场上挂牌交易,代码为'AVTX',而C系列无表决权可转换优先股和权证未在任何交易所上市。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息